Systems-Level Approach to Neuronopathic Lysosomal Storage Disorders
Systems-Level Approach to Neuronopathic Lysosomal Storage Disorders
批准号:
10721768
负责人:
JONATHAN D COOPER
金额:
$160.46万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-15 至 2028-08-31
关键词:
AffectApplications GrantsArtificial IntelligenceAstrocytesAtlasesAutomobile DrivingBehavioralBiochemicalBiochemical PathwayBiogenesisBiologyBrainCLN2 geneCandidate Disease GeneCatalogsCell NucleusCellsCellular Metabolic ProcessCellular StressCentral Nervous SystemCentral Nervous System DiseasesCessation of lifeCommunicationComplexDataDiseaseDisease ProgressionDisease modelEffector CellEnzymesFoundationsFunctional disorderFutureGenesGeneticGenetic TranscriptionGoalsGrowthHealthHumanIndividualInduced pluripotent stem cell derived neuronsInterphase CellInvestigationKnowledgeLinkLipidsLysosomesMacrophageMediatingMembraneMetabolicMetabolic PathwayMethodologyMicrogliaMucopolysaccharidosis III BMutationNerve DegenerationNeurodegenerative DisordersNeuronsNuclearOrganOutcomeOutputPathogenesisPathogenicityPathologicPathway AnalysisPathway interactionsPatientsPhenotypePost-Translational Protein ProcessingProteinsProteomicsRecyclingRegulationRoleRouteSignal PathwaySignal TransductionSiteStressSystemSystems BiologySystems IntegrationTest ResultTestingTherapeuticTissuesTrainingTransgenic MiceTranslational ResearchWorkbrain healthcandidate identificationcell typecellular pathologycombatdisease phenotypeenzyme deficiencyexhausthuman modelindividual responseinnovationknowledge of resultslipidomicslysosomal proteinsmetabolomicsmouse modelnovelnovel therapeuticsprematurepreventprotein protein interactionresponsetherapeutic developmenttherapeutic targettooltranscription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Neuronopathic lysosomal storage disorders (LSDs) are a group of fatal neurodegenerative diseases caused by genetic defects in components of the lysosome, which is the major site within the cell for the degradation and recycling of exhausted cellular components. Defective lysosomes accumulate undegraded storage material, which has classically been thought to be toxic for the cell and the driver of the pathogenic cascade of the dis- ease. Recent advances in the investigation of the lysosome, however, have shown that the storage burden it- self can be uncoupled from the most dramatic effects of the disease on the affected organs. Moreover, there are emerging roles of the lysosome as a central player in the regulation of cell metabolism which are distinct from its classical role as a cellular degradation site. The central hypothesis of this proposal is that are the changes in the communication between the lysosome and the rest of the cell, rather than the storage itself, that drive disease pathogenesis. Determining exactly which components of the lysosomal communication network mediate disease propagation, in which cell type, and how, is important because it could unveil the next generation of therapeutic targets. We propose to use innovative genetic tools and artificial intelligence-driven analytical pipelines to mechanistically investigate changes in lysosomal content and communication in the central nervous system of mouse models of two distinct LSDs. In Aim 1 we will catalogue LSD-associated changes in lysosomal content and composition and determine their relationship with LSD-specific cellular features based on the perturbation of components of the broad lysosomal gene metabolic network. In Aim 2 we will investigate the changes in the signaling network that mediates communication of the lysosome with the nucleus and determine the effectors of the cell’s response to lysosomal stress. In Aim 3 we will place the study of lysosomal content, signaling, and dysfunction in the context of specific cell types (neurons, astroglia, macrophages) to determine their role in the initiation and propagation of disease. Results from this study will provide the first atlas of changes in lysosomal content and signaling components in LSDs and will pioneer the integrative study of the lysosome as a multi-level network of causally associated components and pathways. Knowledge resulting from this study could lay the foundation for future translational investigation of treatments for neuronopathic LSDs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining and treating peripheral nervous system dysfunction in Cln1 disease
-
批准号:10597696
-
项目类别:
-
资助金额:$23.63万
-
财政年份:2022
-
负责人:JONATHAN D COOPER
-
依托单位:
Defining and treating peripheral nervous system dysfunction in Cln1 disease
-
批准号:10428174
-
项目类别:
-
资助金额:$19.69万
-
财政年份:2022
-
负责人:JONATHAN D COOPER
-
依托单位:
Characterizing and testing the efficacy of AAV-mediated gene therapy in a sheep model of CLN1 disease.
-
批准号:10339842
-
项目类别:
-
资助金额:$55.06万
-
财政年份:2022
-
负责人:JONATHAN D COOPER
-
依托单位:
Characterizing and testing the efficacy of AAV-mediated gene therapy in a sheep model of CLN1 disease.
-
批准号:10671454
-
项目类别:
-
资助金额:$52.19万
-
财政年份:2022
-
负责人:JONATHAN D COOPER
-
依托单位:
Characterizing and testing the efficacy of AAV-mediated gene therapy in a novel CRISPR/Cas9 generated sheep model of Cln1 disease.
-
批准号:10357987
-
项目类别:
-
资助金额:$50.24万
-
财政年份:2021
-
负责人:JONATHAN D COOPER
-
依托单位:
Comparative Morphology of Neuronal Ceroid Lipofuscinosis
-
批准号:6618013
-
项目类别:
-
资助金额:$12.83万
-
财政年份:2002
-
负责人:JONATHAN D COOPER
-
依托单位:
Comparative Morphology of Neuronal Ceroid Lipofuscinosis
-
批准号:6789345
-
项目类别:
-
资助金额:$12.83万
-
财政年份:2002
-
负责人:JONATHAN D COOPER
-
依托单位:
Comparative Morphology of Neuronal Ceroid Lipofuscinosis
-
批准号:6471081
-
项目类别:
-
资助金额:$12.83万
-
财政年份:2002
-
负责人:JONATHAN D COOPER
-
依托单位: